AstraZeneca Offers CHOICES Prostate Education Program

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 11
Volume 8
Issue 11

WILMINGTON, Delaware-Astra-Zeneca has launched CHOICES, a comprehensive resource program for men with prostate cancer and their families. The program contains expert advice to help patients make informed treatment choices and real life messages from survivors, the company said in a news release.

WILMINGTON, Delaware—Astra-Zeneca has launched CHOICES, a comprehensive resource program for men with prostate cancer and their families. The program contains expert advice to help patients make informed treatment choices and real life messages from survivors, the company said in a news release.

The CHOICES packet consists of two videocassettes and a short educational booklet.

The first video, Understanding Your Choice, reviews the function of the prostate gland, explains how physicians diagnose prostate cancer, and details the four key treatment selections: surgery, radiation therapy, hormonal therapy, and close surveillance.

The second video, CHOICES We’ve Made, approaches the treatment alternatives through the experiences of four actual prostate cancer patients. Physicians, patients, and family members explain their roles in living with prostate cancer and how they came to their various treatment decisions.

“The CHOICES videos showed me how important my role is in prostate cancer treatment and how that choice can affect my life,” Robert Wilbert, a prostate cancer survivor from Detroit, said in the release. “Now I have a better understanding of the disease and the various therapies I can choose from. After reviewing the tapes with my family, we felt comfortable discussing what method would be best for me.”

CHOICES videos are available to prostate cancer patients through their physicians. Doctors will receive CHOICES materials through their AstraZeneca urology sales representatives.

Recent Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Related Content